| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Wednesday, July 14, 2021 12:10:47 PM
No, company got this data starting in 2019, and Linda Liau, with other top scientists, wrote a whole scientific paper on how to get this data when it needs to be gotten in retrospect.
Since they have known for quite some time that long-term survivors were IDH wild-type and mesenchymal, as discussed off-handedly in multiple LL presentations on YouTube, it is clear they knew this was coming and had been addressing it for some time.
But it’s a biomarker, not something that can’t be determined after the fact, it was driven by the larger community’s greater understanding of the science, so it was not done by NWBO, and it shows that DCVax’ hypothesized, but widely understood to be the case, mechanism works exactly as expected, more mutations, more efficacy.
It only helps, in my view. It puts the icing on the cake. The science is confirmed by the broader community’s independently derived science conclusions. How could that possibly hurt an efficacious drug. It only hurts a bogus drug trying to get over.
Since they have known for quite some time that long-term survivors were IDH wild-type and mesenchymal, as discussed off-handedly in multiple LL presentations on YouTube, it is clear they knew this was coming and had been addressing it for some time.
But it’s a biomarker, not something that can’t be determined after the fact, it was driven by the larger community’s greater understanding of the science, so it was not done by NWBO, and it shows that DCVax’ hypothesized, but widely understood to be the case, mechanism works exactly as expected, more mutations, more efficacy.
It only helps, in my view. It puts the icing on the cake. The science is confirmed by the broader community’s independently derived science conclusions. How could that possibly hurt an efficacious drug. It only hurts a bogus drug trying to get over.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
